San Diego-based Viking Therapeutics marked by itself as a significant competitor from the weight loss drug market place in February soon after revealing promising facts from a mid-stage trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented to be a weekly injection and in March the compa